Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio®) in Participants With Relapsing Forms of Multiple Sclerosis

NCT04410991 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT04410991
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04410991 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio®) in Participants With Relapsing Forms of Multiple Sclerosis
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Completed
Start date
June 11, 2020
Completion date
July 16, 2024
Enrollment
899 (actual)
Sites
186

Conditions

As the registry lists them; a condition with its own page is linked.

relapsing multiple sclerosis